Rola pierwotnej mitomycynowisko-trabekulektomii w operacyjnym leczeniu jaskry wrodzonej
Primary Mitomycinviscotrabeculectomy Role in Congenital Glaucoma Surgical Treatment
Dorota Matusiak, Janusz Czajkowski, Anna Groblewska
Klinika Okulistyki Instytutu "Centrum Zdrowia Matki Polki" w Łodzi Kierownik: prof. dr hab. n. med. Janusz Czajkowski
Summary: The aim of the study was to estimate efficacy and safety of mitomycin C (MMC) use in primary trabeculectomy in congenital glaucoma during one year follow-up. 54 patients (87 eyes) were examined. In group A, 22 patients (36 eyes) underwent surgery with additional intraoperative MMC use. Group B consisted of 32 patients (51 eyes) operated without MMC. In group A mean IOP reduction was 58.65% compared to 47.57% in group B (p<0.001). Mean IOP was also lower in the group A (16.31 mmHg to18.10 mmHg in grup B (p<0.05). The most succesful surgeries were observed in patients with infantile glaucoma (in group A 1.00; in group B 0.92). Less effective were operations in congenital glaucoma associated with systemic diseases (group A 0.89, group B 0.86). The least effective ones were observed in patients with buphthalmus (0.53 in group A, 0.65 in group B). Primary trabeculectomy with MMC was a safe surgical procedure for patients. Side effects occured very rarely. The most common ones were hipotony and schallow anterior chamber. After surgery with MMC statistically more often avascular, cystic bleb was observed, but bleb-related complications were not observed.
Keywords: congenital glaucoma, primary trabeculectomy, mitomycin C